Breaking Barriers to Research Access

April 13, 2026 updated by: The Clatterbridge Cancer Centre NHS Foundation Trust

Understanding and Breaking Barriers to Research Access for Cancer Patients

There is a need to improve accessibility to research and clinical trials within the NHS. Key groups are consistently under-represented in research: those from minority ethnic backgrounds, those with lower socio-economic status and those with impaired capacity. This leads to inequality of healthcare and an inequality of patient experience. Increasing access to research would not only broaden research opportunities and bridge gaps in health equality; diverse research representation means better understanding of disease mechanisms and greater generalisability of findings across the patient population. There are well described socio-economic issues across the region that this trust serves within Cheshire and Merseyside. This brings health challenges for patients. Clatterbridge Cancer Centre is a large networked cancer centre serving Cheshire and Merseyside using a hub model. Research is a core strategic theme; it is hugely important that it is understood not only the areas and hotspots of cancer across the region, but also that patients with those cancers can access a portfolio of research that serves a distinct patient need. Currently there is a lack of such triangulated information within the Trust, which may mean that patient need remains unmet. Therefore the research is designed to understand any barriers that patients may have in accessing research, in tandem with a demographic review and mapping of patient referral and access to the current trials portfolio. This will lead to a truly patient centred approach in accessing research.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

A wide range of participants will be approached, in terms of age, location, disease site and demographics to give a fair reflection of the patient population

Description

Inclusion Criteria:

  • Adults over 18 years. No upper age limit
  • A confirmed diagnosis of cancer
  • Patient planned to or is receiving treatment at The Clatterbridge Cancer Centre NHS Foundation Trust
  • Able to provide informed consent

Exclusion Criteria:

  • Patients with severe co-morbidities considered by the screening team to interfere with the individual's ability to complete requirements of the study or to provide informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Research Barrier Perception and Research Facilitator Perception
Time Frame: 12 Months
The primary outcome measures for the questionnaire portion of the study are the overall scores on Research Barrier Perception (RBP: Questions 7 - 11) and Research Facilitator Perception (RFB: Questions 13 - 17). The predictor variable is deprivation, as measured by the IMD, 2019.
12 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sub-scores of the Research Participation Questionnaire and are Treatment Perception Scores, Practical Consideration Scores Trust scores, Information scores and Impact scores, and their relationship with deprivation
Time Frame: 12 Months
The secondary outcomes relate to the sub-scores of the Research Participation Questionnaire and are Treatment Perception Scores, Practical Consideration Scores Trust scores, Information scores and Impact scores, and their relationship with deprivation (IMD, 2019) will be assessed using a multivariate regression analysis.
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 29, 2024

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

January 8, 2026

First Submitted That Met QC Criteria

January 8, 2026

First Posted (Actual)

January 15, 2026

Study Record Updates

Last Update Posted (Actual)

April 15, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • C1337
  • 321327 (Other Identifier: IRAS)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe